drugset

drugset / Trial / NCT01068392

Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

NCT01068392 ↗

Phase 2 Completed 42 enrolled Dong-A University Hospital Asan Medical Center · collab Chonnam National University Hospital · collab Chung-Ang University · collab Korea Cancer Center Hospital · collab Korea University · collab Kyungpook National University Hospital · collab Samsung Medical Center · collab

NaSingle-groupOpen-labelTreatment

Summary

The investigators are willing to investigate the efficacy and safety of oxaliplatin and prednisolone (Ox-P) combination in patients with previously treated MZL who have a few clinical trial data.

Timeline

Start: 2009-10
Primary completion: 2013-09
Completion: 2014-09

Publications

Oh SY, Kim WS, Kim JS, Chae YS, Lee GW, Eom HS, Ryoo HM, Lee S, Kim SJ, Yoon DH, Won JH, Hong J, Park J, Lee SM, Hong JY, Park E, Kim HJ, Yang DH, Kim HJ, Suh C. A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. Leuk Lymphoma. 2016;57(6):1406-12. doi: 10.3109/10428194.2015.1099650. Epub 2015 Nov 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Subject	Prednisolone	Other / unclassified	100 mg	Oral

Indications